参麦注射液联合环磷腺苷葡胺注射液治疗慢性肺源性心脏病心力衰竭临床研究

Clinical Study in Treatment of Chronic Pulmonale Heart Failure with Shenmai Injection and Meglumine Adenosine Cyclophsphate Injection

目的:探讨参麦注射液联合环磷腺苷葡胺(MAC)注射液治疗慢性肺源性心脏病(简称肺心病)心力衰竭(HF)的临床疗效。方法:将120例肺心病HF患者随机分为治疗组(n=60)和对照组(n=60),两组病例在年龄、性别、临床症状、体征、心功能分级、血气分析、血液流变学及合并症等方面差异无统计学意义(P>0.05)。两组均给予吸氧、祛痰、解痉、平喘、抗炎、利尿剂、扩血管、纠正水电解质紊乱及酸碱平衡失调等常规治疗,治疗组同时加用参麦注射液50 ml加入5%葡萄糖注射液250ml静滴,每日1次,MAC注射液120mg加入5%葡萄糖液250 ml内静滴,每日1次,14天为一疗程。结果:治疗组与对照组相比,治疗后动脉血二氧化碳分压、高切黏度、中切黏度、低切黏度、红细胞聚集指数、红细胞压积、纤维蛋白原明显下降,动脉血氧分压、pH值明显上升,NYHA心功能分级好转,差异均具有统计学意义(P<0.01)。治疗组总有效率95.0%(57/60)与对照组73.3%(44/60)相比差异有统计学意义(P<0.01)。结论:参麦注射液联合MAC注射液治疗肺心病HF可以缩短病程,提高治愈好转率、延长寿命、改善生活质量。具有疗效显著、安全可靠、见效快、疗程短、毒副作用小等诸多优点,值得临床推广应用。

Objective：To explore the clinical curative effect of shenmai injection and meglumine adenosine cyclophsphate（MAC） injection in chronic pulmonary heart disease （i.e.cor pulmonate） heart failure（HF）.Methods：Patients with eor pulmonale HF （n=120） were randomly divides into the treatment group（n=60） and the comparison group（n=60）,Two groups in age, sex, clinical symptoms and signs, cardiac function,blood gas analysis,blood rheology, and complications such as the difference was not statistically significant（P〉0.05）.Two groups were given oxygen,expectorant, antispasmodic,asthma,anti-inflammatory,diuretics,vasodilators, to correct fluid and electrolyte disorders and acid- base balance disorders and other conventional treatment.At the same time,the treatment group was addsed shenmai injection 50 ml plus 5% GS 250 ml intravenous drip,qd,MAC injection 120 mg plus 5% GS 250 ml intravenous drip,qd,14 days for a course of treatment.Results： The treatment group compared with the comparison group,After treatment, arterial carbon dioxide partial pressure, high shear viscosity,the shear viscosity,low shear viscosity,erythrocyte aggregation,hematocrit,fibrinogen decreased,blood pressure, pH value was increased,NYHA cardiac function classification improved, the differences were statistically significant （P〈0.01）.The total effective rate in the treatment group 95.0%（57/60） with the comparison group 73.3%（44/60） compared to significantly （P〈0.01）.Conelusion：shenmai injection and MAC injection treats cor pulmonale HF to may shorten the course,improve the cure rate improved,longer and better quality of life. Have a significant effect,saf e,reliable,quick,short duration of drug side effects and many other advantages,is worthy of clinical application.